Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:16:31.927Z.
Calculation as of: 2026-10-06T14:16:31.927Z.
Quote observation: 2026-10-06T14:15:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$411.75M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$408.44M
EV/Sales Ratio
6.64x
TTM Avg
6.44x
3Y Avg
6.66x
5Y Avg
6.66x
Market Cap
$407.35M
EV/Sales Ratio
N/A
TTM Avg
0.91x
3Y Avg
12.05x
5Y Avg
12.05x
Market Cap
$416.52M
EV/Sales Ratio
0.63x
TTM Avg
0.69x
3Y Avg
1.51x
5Y Avg
2.02x
Market Cap
$396.22M
EV/Sales Ratio
9.57x
TTM Avg
2.21x
3Y Avg
2.18x
5Y Avg
9.49x
Market Cap
$429.68M
EV/Sales Ratio
5.60x
TTM Avg
3.64x
3Y Avg
6.44x
5Y Avg
16.19x
Market Cap
$433.92M
EV/Sales Ratio
N/A
TTM Avg
45.86x
3Y Avg
24.99x
5Y Avg
87.94x
Market Cap
$439.65M
EV/Sales Ratio
5.47x
TTM Avg
5.78x
3Y Avg
4.51x
5Y Avg
5.84x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $411.75M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $410.49M | 6.10x | 3.70x | 3.81x | 3.81x |
| Shoulder Innovations, Inc. (SI)vs › | $408.44M | 6.64x | 6.44x | 6.66x | 6.66x |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $407.35M | N/A | 0.91x | 12.05x | 12.05x |
| Myriad Genetics, Inc. (MYGN)vs › | $416.52M | 0.63x | 0.69x | 1.51x | 2.02x |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $396.22M | 9.57x | 2.21x | 2.18x | 9.49x |
| Editas Medicine, Inc. (EDIT)vs › | $429.68M | 5.60x | 3.64x | 6.44x | 16.19x |
| Capricor Therapeutics, Inc. (CAPR)vs › | $433.92M | N/A | 45.86x | 24.99x | 87.94x |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.65M | 5.47x | 5.78x | 4.51x | 5.84x |
| MapLight Therapeutics, Inc. (MPLT)vs › | $380.98M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
